Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.

Moccia M, Palladino R, Lanzillo R, Carotenuto A, Russo CV, Triassi M, Brescia Morra V.

PLoS One. 2017 Jan 5;12(1):e0169489. doi: 10.1371/journal.pone.0169489.

2.

Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis.

Lanzillo R, Di Somma C, Quarantelli M, Carotenuto A, Pivonello C, Moccia M, Cianflone A, Marsili A, Puorro G, Saccà F, Russo CV, De Luca Picione C, Ausiello F, Colao A, Brescia Morra V.

Eur J Neurol. 2017 Feb;24(2):446-449. doi: 10.1111/ene.13207.

PMID:
27982500
3.

A longitudinal real-life comparison study of natalizumab and fingolimod.

Lanzillo R, Carotenuto A, Moccia M, Saccà F, Russo CV, Massarelli M, De Rosa A, Brescia Morra V.

Acta Neurol Scand. 2016 Dec 15. doi: 10.1111/ane.12718. [Epub ahead of print]

PMID:
27976804
4.

Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.

Moccia M, Palladino R, Carotenuto A, Russo CV, Triassi M, Lanzillo R, Brescia Morra V.

Mult Scler Relat Disord. 2016 Nov;10:90-96. doi: 10.1016/j.msard.2016.09.011.

PMID:
27919507
5.

The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.

Saccà F, Costabile T, Carotenuto A, Lanzillo R, Moccia M, Pane C, Russo CV, Barbarulo AM, Casertano S, Rossi F, Signoriello E, Lus G, Brescia Morra V.

Mult Scler. 2016 Nov 3. pii: 1352458516677592. [Epub ahead of print]

PMID:
27811338
6.

Functional MRI signal fluctuations highlight altered resting brain activity in Huntington's disease.

Sarappa C, Salvatore E, Filla A, Cocozza S, Russo CV, Saccà F, Brunetti A, De Michele G, Quarantelli M.

Brain Imaging Behav. 2016 Oct 12. [Epub ahead of print]

PMID:
27734308
7.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network..

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944.

PMID:
27402890
8.

Mobitz type I and II atrioventricular blocks during fingolimod therapy.

Saccà F, Puorro G, Marsili A, Pane C, Russo CV, Lanzillo R, de Rosa A, Cittadini A, De Angelis G, Brescia Morra V.

Neurol Sci. 2016 Sep;37(9):1557-9. doi: 10.1007/s10072-016-2621-y.

PMID:
27225279
9.

Comprehensive Evaluation of Plasma 7-Ketocholesterol and Cholestan-3β,5α,6β-Triol in an Italian Cohort of Patients Affected by Niemann-Pick Disease due to NPC1 and SMPD1 Mutations.

Romanello M, Zampieri S, Bortolotti N, Deroma L, Sechi A, Fiumara A, Parini R, Borroni B, Brancati F, Bruni A, Russo CV, Bordugo A, Bembi B, Dardis A.

Clin Chim Acta. 2016 Apr 1;455:39-45. doi: 10.1016/j.cca.2016.01.003.

PMID:
26790753
10.

Modifications of resting state networks in spinocerebellar ataxia type 2.

Cocozza S, Saccà F, Cervo A, Marsili A, Russo CV, Giorgio SM, De Michele G, Filla A, Brunetti A, Quarantelli M.

Mov Disord. 2015 Sep;30(10):1382-90. doi: 10.1002/mds.26284.

PMID:
26094751
11.

A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2.

Saccà F, Puorro G, Brunetti A, Capasso G, Cervo A, Cocozza S, de Leva M, Marsili A, Pane C, Quarantelli M, Russo CV, Trepiccione F, De Michele G, Filla A, Morra VB.

J Neurol. 2015 Jan;262(1):149-53. doi: 10.1007/s00415-014-7551-0.

PMID:
25346067
12.

A novel PSEN1 mutation in a patient with sporadic early-onset Alzheimer's disease and prominent cerebellar ataxia.

Testi S, Peluso S, Fabrizi GM, Antenora A, Russo CV, Pappatà S, Padovani A, Ferrarini M, Filla A.

J Alzheimers Dis. 2014;41(3):709-14. doi: 10.3233/JAD-140081.

PMID:
24718101
13.

Central cholinergic dysfunction in the adult form of Niemann Pick disease type C: a further link with Alzheimer's disease?

Manganelli F, Dubbioso R, Iodice R, Topa A, Dardis A, Russo CV, Ruggiero L, Tozza S, Filla A, Santoro L.

J Neurol. 2014 Apr;261(4):804-8. doi: 10.1007/s00415-014-7282-2.

PMID:
24570279
14.

Default-mode network changes in Huntington's disease: an integrated MRI study of functional connectivity and morphometry.

Quarantelli M, Salvatore E, Giorgio SM, Filla A, Cervo A, Russo CV, Cocozza S, Massarelli M, Brunetti A, De Michele G.

PLoS One. 2013 Aug 19;8(8):e72159. doi: 10.1371/journal.pone.0072159.

15.

Suicidal ideation in a European Huntington's disease population.

Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network..

J Affect Disord. 2013 Oct;151(1):248-58. doi: 10.1016/j.jad.2013.06.001.

16.

Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington's disease patients.

Russo CV, Salvatore E, Saccà F, Tucci T, Rinaldi C, Sorrentino P, Massarelli M, Rossi F, Savastano S, Di Maio L, Filla A, Colao A, De Michele G.

J Huntingtons Dis. 2013;2(4):501-7. doi: 10.3233/JHD-130078.

PMID:
25062734
17.

β-Defensin genomic copy number does not influence the age of onset in Huntington's Disease.

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; Registry investigators of the European Huntington's Disease Network..

J Huntingtons Dis. 2013;2(1):107-24. doi: 10.3233/JHD-130002.

PMID:
25057107
18.

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network..

JAMA Neurol. 2013 Jan;70(1):25-33. doi: 10.1001/2013.jamaneurol.382.

PMID:
23108692
19.

A randomized clinical trial of lithium in multiple system atrophy.

Saccà F, Marsili A, Quarantelli M, Brescia Morra V, Brunetti A, Carbone R, Pane C, Puorro G, Russo CV, Salvatore E, Tucci T, De Michele G, Filla A.

J Neurol. 2013 Feb;260(2):458-61. doi: 10.1007/s00415-012-6655-7.

PMID:
22932748
20.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG)., Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network., Myers RH; HD-MAPS Study Group., MacDonald ME, Gusella JF; COHORT study of the HSG..

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683.

Items per page

Supplemental Content

Loading ...
Support Center